Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: a FIGARO-DKD subgroup analysis

Figures

• 

  Figure 1. (A) Incidence of the primary CV composite outcome (time to first CV death, non-fatal stroke, non-fatal MI, and HHF) in the Chinese subgroup. (B) Incidence of the primary CV composite outcome (time to first CV death, non-fatal stroke, non-fatal MI, and HHF) and its components in the Chinese subgroup and the overall population. CI, confidence interval; CV, cardiovascular; HHF, hospitalization for heart failure; HR, hazard ratio; MI, myocardial infarction; PY, patient-years.

• 

  Figure 2. (A) Incidence of the key secondary kidney composite outcome (time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death) in the Chinese subgroup. (B) Incidence of the key secondary kidney composite outcome (time to kidney failure, sustained ≥40% decrease in eGFR from baseline, or kidney-related death), and its components in the Chinese subgroup and the overall population. (C) Incidence of the additional secondary kidney composite outcome (time to kidney failure, sustained eGFR decline ≥57% from baseline over ≥4 weeks, or kidney-related death) and the sustained eGFR decline ≥57% component in the Chinese subgroup. CI, confidence interval; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HR, hazard ratio; PY, patient-years.

• 

  Figure 3. (A) Change in UACR from baseline in the Chinese subgroup over time. (B) Change in eGFR from baseline in the Chinese subgroup over time. The LS mean and 95% CI were derived from a mixed model with the following factors: treatment arm, region, screening eGFR category, screening albuminuria type, time, time to treatment and log-transition baseline value that matches the screen-phase albuminuria type; and with logarithmic-transformed baseline value × time as covariate. Independent unstructured covariance patterns were estimated for each treatment arm. This analysis excluded values after the date of end-stage kidney disease. CI, confidence interval; eGFR, estimated glomerular filtration rate; LS, least-squares; UACR, urine albumin-to-creatinine ratio.